Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 240

recruiting
3 982
countries
28
conditions
2 106

3 662 trials match your criteria

Duchenne muscular dystrophy gene carrier

Not recruiting

Study to Determine the Best Dose of Vesleteplirsen for Patients with Duchenne Muscular Dystrophy Suitable for Exon 51-Skipping Treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Vesleteplirsen

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-obstructive cardiomyopathy

Not recruiting

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten

Huntington's disease

Not recruiting

Study on the Safety and Effects of PTC518 for Patients with Huntington's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:PTC518

Immune thrombocytopenia

Not recruiting

Long-term Study on the Safety and Efficacy of Efgartigimod in Adults with Primary Immune Thrombocytopenia

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

Short stature

Not recruiting

Study on the Effects of Somapacitan and Somatropin in Children with Short Stature Born Small for Gestational Age Without Catch-Up Growth by Age 2

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Somapacitan

Myelofibrosis

Not recruiting

Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan

Myasthenia gravis

Not recruiting

Study on the Effects of Inebilizumab for Adults with Myasthenia Gravis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab

Diabetic nephropathy

Not recruiting

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin

Acute myeloid leukaemia

Not recruiting

Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cytarabine

Gastric cancer+1

Not recruiting

Study on the Safety and Activity of S095029 and Pembrolizumab for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.